Crossject expands executive board to five with Lacombe, Morin, Seltz appointments
Bitget2026/09/25 05:30- Crossject expanded its Executive Board to five members, appointing Olivier Lacombe, Didier Morin, Lionel Seltz with immediate effect.
- Lacombe joined in 2021, bringing 21 years in pharmaceutical development from Fournier, Abbott, Solvay, Inventiva.
- Morin joined in 2023, bringing 30 years in industrial operations from IDS, Axess Vision.
- Seltz joined in January 2026, bringing 25 years in life sciences finance from Cegedim, IQVIA/IMS Health, Mars Group.
- Crossject US appointed David Pudwill as VP, Regulatory & Scientific Affairs; he brings about 20 years’ experience, including nine at the FDA.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Crypto prices
More
